Everything below concerns Sirtuin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
NAD+ is a dinucleotide composed of two nucleotides joined by a pyrophosphate linkage. One nucleotide contains adenine, and the other contains nicotinamide. The oxidized form carries a positive charge on the nicotinamide ring and is abbreviated NAD+. It functions as a cofactor in hydride-transfer reactions, accepting electrons in catabolic pathways. In cells, it interconverts with reduced NADH, forming a redox couple central to energy metabolism. The molecule is water-soluble and does not cross cell membranes freely without specific transport or precursor pathways.
The nicotinamide ring undergoes reversible reduction at the para position, converting NAD+ to NADH. This reaction transfers a hydride equivalent, not a free hydrogen atom or electron alone. Because the redox pair has a defined reduction potential, it links oxidation of fuels to respiratory chain activity. Many dehydrogenases use NAD+ as a co-substrate and produce NADH. The ratio of NAD+ to NADH reflects metabolic state and influences flux through several pathways.
NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a coenzyme built from two nucleotides joined by a phosphate linkage. One nucleotide carries adenine, and the other carries nicotinamide; the plus sign denotes a formal positive charge on the nicotinamide ring, not a free proton. In cells, NAD+ and its reduced partner NADH form a reversible redox pair. That pair participates in electron transfer reactions throughout metabolism. The abbreviation NAD+ is common in biochemistry, while NAD(H) sometimes denotes the combined pool.
The molecule was first described in the early twentieth century as a factor that promoted fermentation in yeast extracts. Later work linked it to hydrogen transfer and to the oxidation of nutrients in living tissues. Its structure was resolved as a dinucleotide, which explained why it could accept and donate electrons at specific enzyme sites. Today, NAD+ is recognized as a central substrate and signaling precursor, not merely a metabolic cofactor. Whether all observed NAD+ changes reflect causal signaling remains an open question.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | Nicotinamide adenine dinucleotide | Oxidized dinucleotide form |
| CAS Registry Number | 53-84-9 | Common entry for beta-NAD+ |
| Molecular formula | C21H27N7O14P2 | Free acid form |
| Molar mass | 663.43 g/mol | Calculated for free acid |
| Water solubility | Freely soluble | Charged dinucleotide; less soluble in organic solvents |
Measuring NAD+ in biological samples requires care because the molecule is chemically reactive and present at low concentrations in some tissues. Common approaches include enzymatic cycling assays, high-performance liquid chromatography, and liquid chromatography coupled to mass spectrometry. Each method has different sensitivity and specificity, and sample preparation can affect results. Acidic or alkaline extraction steps are used in some protocols, but the choice depends on the analyte and matrix. No single method is universally optimal for every tissue or fluid.
Solid NAD+ is relatively stable when kept dry, cold, and protected from light. Aqueous solutions are more vulnerable to hydrolysis and can lose activity during repeated freeze-thaw cycles or prolonged storage at ambient temperature. Stability depends on pH, ionic strength, and the presence of degrading enzymes or metal ions. For many laboratory uses, aliquots are stored frozen and thawed only once. Exact degradation rates vary by matrix, so stability should be checked for each application rather than assumed.
In glycolysis, NAD+ accepts electrons during the oxidation of glyceraldehyde-3-phosphate, forming NADH. The tricarboxylic acid cycle and fatty acid oxidation also generate NADH, which donates electrons to the mitochondrial electron transport chain. This flow supports ATP synthesis and helps maintain the redox balance of the cell. Other dehydrogenases use NAD+ as a cofactor for biosynthetic reductions and detoxification reactions. NADH is later reoxidized to sustain continued flux through these pathways.
Beyond electron transfer, NAD+ serves as a substrate for enzymes that cleave the molecule and transfer ADP-ribose units. Sirtuins, poly(ADP-ribose) polymerases, and CD38 consume NAD+ in regulatory reactions. These activities link NAD+ availability to DNA repair, chromatin modification, calcium signaling, and metabolic stress responses. Because consumption can exceed biosynthesis under some conditions, cellular NAD+ levels are dynamic rather than fixed. Enzyme affinity and local synthesis also influence how much NAD+ is available for signaling.
Although the nomenclature system became a convention, hemoglobin D, in particular, became known by various names, generally based on their origin of identification; like hemoglobin D-Los Angeles for the first discovered, hemoglobin D-Punjab, D-North Carolina, D-Portugal, D-Oak Ridge, and D-Chicago. By 1961, it was known that the structural difference of HbD from HbA was in the β-chain. Around the same time, Corrado Baglioni of Massachusetts Institute of Technology identified the exact abnormality that substitution of glutamic acid with glutamine at position 121 in the β-chain was the basis of HbD, the findings which he reported in 1962.
Therefore almost all patients will in addition require immunosuppressants, such as prednisone, mycophenolate or azathioprine, as acetylcholinesterase inhibitors alone are insufficient. The surgical removal of the thymus may improve symptoms in certain cases. Plasmapheresis and high-dose intravenous immunoglobulin may be used when oral medications are insufficient to treat severe symptoms, including during sudden flares of the condition. On rare occasions the respiratory muscles can become significantly weak, subsequent mechanical ventilation may then be required. Once intubated, acetylcholinesterase inhibitors may be temporarily withheld to reduce airway secretions. Myasthenia gravis affects 50 to 200 people per million. It is newly diagnosed in 3 to 30 people per million each year. Increased awareness has made diagnosis more common. Myasthenia gravis most commonly occurs in women under the age of 40 and in men over the age of 60. It is uncommon in children. With treatment, most have fulfilling lives and have a normal life expectancy. The word is from the Greek mys, "muscle" and asthenia "weakness", and the Latin gravis, "serious".
The Statute of the Court and TFEU require judges are appointed only if they have no political occupation, with independence "beyond doubt". They are selected for renewable six-year terms by "common accord" of governments, with the advice of seven EU or member state judges that the Council and Parliament selects. The Rules of Procedure of the Court of Justice, article 11, says the court is usually organised into chambers of 3 or 5 judges each. A "grand chamber" of 15 more senior judges sit on questions of "difficulty or importance", or those requested by member states. The court's president and vice-president are elected by other judges for renewable 3-year terms by secret ballot. Judges can only be dismissed if all other judges and Advocates General unanimously agree. Advocates General are appointed by the court to give reasoned submissions on cases, especially involving new points of law. Unlike judges on the Court, they write opinions as themselves, rather than collectively, and often with a command of prose and reason, and while not binding are often followed in practice. In addition, each judge has secretaries or referendaires who research and write. Unlike the UK where judges always write their own opinions, referendaires often assist drafting the judgments in the Court of Justice. The Court's Translation Directorate will translate every final judgment into the 24 official languages of the European Union.
Sources: en.wikipedia.org
==== By carbon dioxide ==== Since carbon dioxide and oxygen compete at the active site of RuBisCO, carbon fixation by RuBisCO can be enhanced by increasing the carbon dioxide level in the compartment containing RuBisCO (chloroplast stroma). Several times during the evolution of plants, mechanisms have evolved for increasing the level of carbon dioxide in the stroma (see C4 carbon fixation). The use of oxygen as a substrate appears to be a puzzling process, since it seems to throw away captured energy. However, it may be a mechanism for preventing carbohydrate overload during periods of high light flux. This weakness in the enzyme is the cause of photorespiration, such that healthy leaves in bright light may have zero net carbon fixation when the ratio of O2 to CO2 available to RuBisCO shifts too far towards oxygen. This phenomenon is primarily temperature-dependent: high temperatures can decrease the concentration of CO2 dissolved in the moisture of leaf tissues. This phenomenon is also related to water stress: since plant leaves are evaporatively cooled, limited water causes high leaf temperatures. C4 plants use the enzyme PEP carboxylase initially, which has a higher affinity for CO2. The process first makes a 4-carbon intermediate compound, hence the name C4 plants, which is shuttled into a site of C3 photosynthesis then decarboxylated, releasing CO2 to boost the concentration of CO2. Crassulacean acid metabolism (CAM) plants keep their stomata closed during the day, which conserves water but prevents the light-independent reactions (a.k.a.
Degeneracy or redundancy of codons is the redundancy of the genetic code, exhibited as the multiplicity of three-base pair codon combinations that specify an amino acid. The degeneracy of the genetic code is what accounts for the existence of synonymous mutations.
1989–1991 – 1.3 L (1,323 cc) B3, 1 barrel, 8-valve, 76 PS (56 kW) / 101 N⋅m (74 lb⋅ft) 1991–1994 – 1.3 L (1,323 cc) B3, EGI-S, 8-valve, 79 PS (58 kW) / 103 N⋅m (76 lb⋅ft) 1989–1991 – 1.5 L (1,498 cc) B5-M, carburetor, 16-valve, 91 PS (67 kW) / 122 N⋅m (90 lb⋅ft) 1990–1994 – 1.5 L (1,498 cc) B5-MI, EGI-S, 16-valve 94 PS (69 kW) / 123 N⋅m (91 lb⋅ft) 1989–1991 – 1.5 L (1,498 cc) B5-DE, EFi, 16-valve DOHC, 110 PS (81 kW) / 127 N⋅m (94 lb⋅ft) 1991–1994 – 1.5 L (1,498 cc) B5-DE, EFi, 16-valve DOHC, 115–120 PS (85–88 kW) / 132 N⋅m (97 lb⋅ft) (lower power for AT cars) 1989–1991 – 1.6 L (1,597 cc) B6, 1 barrel, 8-valve, 85 hp (63 kW; 86 PS) / 92 lb⋅ft (125 N⋅m) 1989–1994 – 1.6 L (1,597 cc) B6, carburetor, 16-valve, SOHC, 103 hp (77 kW; 104 PS) / 108 lb⋅ft (146 N⋅m) 1989–1994 – 1.8 L (1,839 cc) BP, FI, 16-valve DOHC, 140 hp (104 kW; 142 PS) / 118 lb⋅ft (160 N⋅m) 1989–1994 – 1.8 L (1,839 cc) BPT, FI, 16-valve DOHC, turbo, 180 PS (132 kW) / 237 N⋅m (175 lb⋅ft) (Familia GT-X) 1991–1994 – 1.8 L (1,839 cc) B8, FI, 16-valve SOHC, 103 hp (77 kW) 1992–1993 – 1.8 L (1,839 cc) BPD, FI, 16-valve DOHC, turbo, 210 PS (154 kW) / 255 N⋅m (188 lb⋅ft) (Familia GT-R & GT-Ae) 1989–1994 – 1.7 L (1,720 cc) PN, Diesel, 8-valve, 57 PS (42 kW) / 112 N⋅m (83 lb⋅ft) (European specs)
Sources: en.wikipedia.org
NAD+ is the oxidized form, while NADH is the reduced form carrying an added hydride. The two form a redox pair that cells use in many energy-yielding reactions.
NAD+ is a small organic cofactor, not a protein or enzyme. It binds temporarily to enzymes such as dehydrogenases to assist electron transfer.
Intact NAD+ is generally not taken up efficiently by most cells because it is charged and water-soluble. Cells often rely on precursors such as nicotinamide or nicotinamide riboside to produce NAD+ internally.
It indicates a formal positive charge on the nicotinamide ring. The molecule is not simply a protonated acid, and the charge is part of its redox chemistry.